Results 51 to 60 of about 9,672 (236)
Hepatology Research, Volume 56, Issue 2, Page 161-171, February 2026.Higher pre‐treatment liver stiffness measurement (LSM) values, rather than post‐treatment values, independently predicts hepatocellular carcinoma after hepatitis C virus eradication, underscoring the need for continued surveillance in patients with elevated baseline LSM.
Takuma Nakatsuka +12 more
wiley +1 more source
Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]
, 2018 Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core +1 more source
Bee products as alternatives in the treatment of viral infections
Journal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba +3 more
wiley +1 more source
Journal of Virus Eradication, 2020 Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber +3 more
doaj +1 more source
Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. [PDF]
, 2015 Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir.
Jakab, Simona +4 more
core +1 more source
Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li +3 more
wiley +1 more source
TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. [PDF]
, 2017 Differentiation and fate of virus-specific CD8(+) T cells after cessation of chronic antigen stimulation is unclear. Here we show that a TCF1(+)CD127(+)PD1(+) hepatitis C virus (HCV)-specific CD8(+) T-cell subset exists in chronically infected patients ...
Emmerich, F. +9 more
core +1 more source
A hepatitis C-vírus-fertőzés és kezelésének költségvonzata [PDF]
, 2015 Absztrakt A hepatitis C-vírus-fertőzés a Föld lakosságának 2–3%-át érinti és a betegséghez társuló egyéni következmények mellett igen jelentős össztársadalmi gazdasági problémát jelent.
Hunyady, Béla, Makara, Mihály
core +1 more source
The Journal of Clinical Pharmacology, Volume 65, Issue 11, Page 1381-1391, November 2025.Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara +4 more
wiley +1 more source
Infection and Drug Resistance, 2018 Ossama A Ahmed,1 Hany H Kaisar,1 Rehab Badawi,2 Nehad Hawash,2 Hossam Samir,1 Sherif ST Shabana,1 Mohamed Hassan A Fouad,1 Fatma H Rizk,3 Samy A Khodeir,4 Sherief Abd-Elsalam2 1Department of Internal Medicine, Faculty of Medicine, Ain Shams University ...
Ahmed OA +9 more
doaj